HAM
CRSP icon

HHR Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

HHR Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-35,370
Closed -$5.42M – 37
2020
Q4 		$5.42M Sell
35,370
-12,260
-26% -$1.45M 0.46% 32
2020
Q3 		$3.98M Sell
47,630
-3,740
-7% -$332K 0.4% 28
2020
Q2 		$3.77M Sell
51,370
-7,300
-12% -$427K 0.37% 30
2020
Q1 		$2.49M Hold
58,670
– – 0.28% 34
2019
Q4 		$3.57M Sell
58,670
-5,860
-9% -$320K 0.34% 27
2019
Q3 		$2.65M Hold
64,530
– – 0.27% 25
2019
Q2 		$3.04M Buy
+64,530
New +$2.58M 0.23% 38

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

HHR Asset Management's CRSP Position: Q1 2021 in Review

HHR Asset Management sold out of CRISPR Therapeutics (CRSP) in Q1 2021, closing a stake of 35,370 shares — an estimated $5.42M sold.

HHR Asset Management first reported a position in CRSP in Q2 2019 and held it in 7 quarters. The position peaked at $5.42M in Q4 2020. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

  • HHR Asset Management reported no remaining CRISPR Therapeutics position as of Q1 2021 after selling out during the quarter.
  • HHR Asset Management sold 35,370 CRISPR Therapeutics shares in Q1 2021, an estimated $5.42M.
  • HHR Asset Management first reported a position in CRISPR Therapeutics in Q2 2019 and held it in 7 quarters.
  • HHR Asset Management's CRISPR Therapeutics position peaked at $5.42M in Q4 2020.
  • 443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on HHR Asset Management's 13F filing for Q1 2021, filed 17 May 2021.